Insight Genetics Announces Promotions for Two Team Members
News Aug 21, 2014
Insight Genetics researches, develops and commercializes diagnostic tests that guide physicians in their diagnoses, treatment selections, and resistance monitoring for specific populations of cancer patients. Insight Genetics has recently expanded its R&D team to include 6 new members.
“Kasey and Tyler have been great additions to the Insight Genetics team,” said Christopher Callaghan, President and COO of Insight Genetics. “They have played integral roles in our laboratory operations and contributed significantly to our development of companion diagnostics in cancer. We are pleased to recognize their work and promote them to new roles within our company.”
As Research Scientist, Tyler Nielsen will coordinate projects and manage resources in Insight Genetics’ research laboratory for the development of companion diagnostics. Nielsen brings extensive knowledge and skills in molecular diagnostic procedures, concepts and practices to his scientific team. Prior to this new role, Nielsen was a Research Associate III. He received his M.A. in biomedical science from Des Moines University.
Kasey Lawrence, Senior Technology Specialist, is responsible for organizing and overseeing day-to-day operations of Insight Genetics’ Next Generation Sequencing program. Previously, Lawrence was a Research Associate III. He holds a bachelor of science in biology from Tennessee Tech University.
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE
New Rapid-fire Method Using Pathology Images & Tumor Data May Help Guide Cancer TherapiesNews
By combining data on pathology images of 13 types of cancer and correlating that with clinical and genomic data, researchers are able to identify tumor-infiltrating lymphocytes, which will enable cancer specialists to generate tumor-immune information from routinely gathered pathology slides.READ MORE